Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
eNq1mF1v2jAUhu/5FVHuiQtroUyBamPthtRqjII27QaZ5FCcGTv1Bx/79XMIaDA56mrqy8TOe058Xj8+cnyzWdJgBUISzrphI7oIA2AJTwl76oaT8V39Orzp1eIMr/DRNDMvajbDIKFYym5YjEYzwExGPx7uP4H5HkTYqwUxn2WQqJN5WhEafcFy8YDzYk4QrzhJgyWoBU+7Ya7V7m0QSyVMFr01F79kjhOI0f7N8Wg2vTx+H6NC7D9UtQRxj9mTVRSYk2aihQCm+ljBExfbinzfOWkTOQLJtUhgiNViKPiKpJBaQ8wxleAUZL5OH0GsKKgiiFUcZclSOonjDG9G8DywJ/3BjPbVRtUv6o1247LdaFxddS6bLadQ4mip7FUwP4GS6XWr1e40ETCUSUTJDGXPGsQ2SjiTnEKUScdaDblQmHqqEpH9U6N5iiPg+UU3pETmFG/NSuWuS4UFNsMgDA78/UjxB2NhAEXNmv2jzzSl6JVZT/b48JRxQac+10xVUORu5LoQfc4UbKor6gY+tdl7kYB8O9nfnNmhP9QzShJXxBkIaZBqMhpUE84nHD5iCRPhjw7fCUv5Wr49dY6r7Cn7fAdOq2gu0sa02blumZPBeVP9NJaqOIFuteA5IMMjIs/BzIDN+bmAMS61Sx086s2eu76IJ5hCRWc0dWSP8eWhkfPmfH+7qhywin6+Hbva5VtRscfdo1WapN1Dod247AP2xpuVeb/e6eWG99Iya2EHyUKpXL5HaL1eRwss6xKbVYrmwjv4j85efw28lwO+bHhKeHpKfVaeiq+rmOvGe6kFOLet3X+/b5+tMZTQcEYtSkZ7I+ng9u3h/Len9Zb28IQm/sLs+k+sCGe++iA9syqedRyYsrI7YfjwdT4nFfcplbaMUXmX06vFqLjH6dX+AMrF/TQ=
hM30xVyEM5DdguJb